Source: Optimi Health
  • Optimi Health Corp. (OPTI) gets amendment for its controlled substances dealer’s licence
  • Optimi can now expand its capacity to produce natural GMP psilocybin
  • The amendment also introduces a provision to extract psilocin for use in clinical trials
  • It can hold 5000 kilograms of dried psilocybin mushrooms and 100 grams of psilocin
  • Optimi Health Corp. (OPTI) is up 1.85 per cent trading at $0.27 per share as of 2:03 p.m. ET

Optimi Health Corp. (OPTI) has been granted an amendment to its controlled substances dealer’s licence by Health Canada.

The amendment enables Optimi to further expand its capacity to produce natural GMP psilocybin at its Princeton, British Columbia facility, as well as introducing a provision to extract psilocin for use in clinical trials.

Under the terms of the amendment, the company is now permitted to possess a quota of up to 5000 kilograms of dried psilocybin mushrooms (10 kilograms of psilocybin equivalent) and 100 grams of psilocin.

Optimi’s subsidiary requested the amendment to ensure adequate supply for licensed companies starting molecular development research and phase 2a and 2b clinical trials investigating the treatment of addictions and mental health conditions. The strategy is part of the company’s goal to commercialize its operations this year.

Optimi’s operational presence now includes 20,000 square feet of technologically advanced aeroponics facilities dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms.

Optimi CEO, Bill Ciprick, commented,

“This approval from federal health authorities for an effective doubling of our growing potential is an important milestone in Optimi’s planned year of commercialization… Optimi prides itself on the efficacy of our ongoing dialogue with regulators working towards the mutual goal of ensuring the highest operational standards and the safety and quality of our various strains of GMP mushrooms for use by approved entities.”

Additionally, the facility is classified as a Level 8 Security Environ with an allowance of $50 million worth of product to be stored on site.

Optimi Health Corp. (OPTI) is up 1.85 per cent trading at $0.27 per share as of 2:03 p.m. ET.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.